Guilin Sanjin Pharmaceutical Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000DY9
CNY
15.28
0.06 (0.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
2,156.75
2,134.27
1,923.65
1,708.42
1,536.08
1,610.60
1,550.13
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
2,156.75
2,134.27
1,923.65
1,708.42
1,536.08
1,610.60
1,550.13
Raw Material Cost
621.08
633.37
620.98
482.62
480.00
481.60
462.06
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
400.36
454.08
498.12
371.15
320.19
291.77
250.62
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
14.09
16.70
20.58
18.98
11.69
5.77
5.53
Selling and Distribution Expenses
880.74
896.46
787.74
706.04
600.94
599.14
555.29
Other Expenses
-26.22
-33.55
-32.50
-20.67
-19.04
-20.58
-20.04
Total Expenditure (Excl Depreciation)
1,654.11
1,665.14
1,602.40
1,372.10
1,222.38
1,172.46
1,073.09
Operating Profit (PBDIT) excl Other Income
502.59999999999997
469.09999999999997
321.2
336.3
313.7
438.1
477
Other Income
175.04
74.76
150.92
127.68
46.01
57.44
50.89
Operating Profit (PBDIT)
781.72
659.57
590.61
567.03
441.90
588.01
605.13
Interest
14.09
16.70
20.58
18.98
11.69
5.77
5.53
Exceptional Items
4.75
1.28
0.18
-6.01
1.34
-1.03
-0.95
Gross Profit (PBDT)
1,535.67
1,500.90
1,302.67
1,225.80
1,056.08
1,129.01
1,088.07
Depreciation
126.48
124.73
124.04
112.99
82.38
92.54
77.21
Profit Before Tax
645.89
519.42
446.18
429.05
349.16
488.67
521.44
Tax
122.40
96.99
116.65
85.34
67.14
75.49
82.34
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
521.53
421.30
329.53
343.72
277.02
392.14
413.35
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
521.53
421.30
329.53
343.72
277.02
392.14
413.35
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
521.53
421.30
329.53
343.72
277.02
392.14
413.35
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
0.0
0.0
Reserves
3,009.78
2,816.96
2,813.33
2,839.82
2,959.00
2,815.44
2,806.66
Earnings per share (EPS)
0.89
0.72
0.56
0.6
0.48
0.0
0.0
Diluted Earnings per share
0.89
0.72
0.56
0.6
0.48
0.0
0.0
Operating Profit Margin (Excl OI)
22.26%
21.56%
16.41%
19.1%
20.41%
27.2%
30.77%
Gross Profit Margin
35.81%
30.18%
29.64%
31.73%
28.09%
36.09%
38.62%
PAT Margin
24.18%
19.74%
17.13%
20.12%
18.03%
24.35%
26.67%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 1.05% vs 10.95% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 23.78% vs 27.86% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 3.74% vs 33.00% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -15.57% vs -18.93% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Guilin Sanjin Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
2,156.75
0
2,156.75
Other Operating Income
0.00
0.00
0.00
Total Operating income
2,156.75
0
2,156.75
Raw Material Cost
621.08
0
621.08
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
400.36
0
400.36
Power Cost
0
0
0.00
Manufacturing Expenses
14.09
0
14.09
Selling and Distribution Expenses
880.74
0
880.74
Other Expenses
-26.22
0.00
-26.22
Total Expenditure (Excl Depreciation)
1,654.11
0
1,654.11
Operating Profit (PBDIT) excl Other Income
502.64
0.00
502.64
Other Income
175.04
0
175.04
Operating Profit (PBDIT)
781.72
0
781.72
Interest
14.09
0
14.09
Exceptional Items
4.75
0
4.75
Gross Profit (PBDT)
1,535.67
0
1,535.67
Depreciation
126.48
0
126.48
Profit Before Tax
645.89
0
645.89
Tax
122.40
0
122.40
Provisions and contingencies
0
0
0.00
Profit After Tax
521.53
0
521.53
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
521.53
0
521.53
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
521.53
0
521.53
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
3,009.78
0
3,009.78
Earnings per share (EPS)
0.89
0
0.89
Diluted Earnings per share
0.89
0
0.89
Operating Profit Margin (Excl OI)
22.26%
0%
0.00
22.26%
Gross Profit Margin
35.81%
0%
0.00
35.81%
PAT Margin
24.18%
0%
0.00
24.18%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 215.68 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 1.05% vs 10.95% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 52.15 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 23.78% vs 27.86% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 60.67 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 3.74% vs 33.00% in Dec 2023

Annual - Interest
Interest 1.41 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -15.57% vs -18.93% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 22.26%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023